Horisberger Alice, Moi Laura, Ribi Camillo, Comte Denis
Service d'immunologie et allergologie, Département de médecine interne, CHUV, 1011 Lausanne.
Rev Med Suisse. 2020 Apr 29;16(N° 691-2):827-830.
Patient suffering from autoimmune diseases (AID) typically have an increased risk of infection, which is attributed to the disease itself, but also to immunosuppressive drugs (IS) and comorbidities. During the current COVID-19 outbreak, the way to manage these diseases remains elusive. Limited data is currently available on AID and IS in the context of this new coronavirus infection. To date, there is no evidence to support an increase in complications of COVID-19 in these patients. In addition, certain drugs that are commonly used to treat AID could be part of the therapeutic arsenal used in COVID-19. The purpose of this article is to review the unique aspects of patients with AID during the COVID-19 outbreak.
患有自身免疫性疾病（AID）的患者通常感染风险会增加，这既归因于疾病本身，也与免疫抑制药物（IS）和合并症有关。在当前新冠疫情期间，管理这些疾病的方法仍不明确。目前关于新型冠状病毒感染背景下的AID和IS的可用数据有限。迄今为止，没有证据支持这些患者中新冠并发症增加。此外，某些常用于治疗AID的药物可能是新冠治疗药物库的一部分。本文旨在综述新冠疫情期间AID患者的独特情况。
